Inflammatix
  • TriVerity
  • Education
    • Acute Infection & Sepsis
    • Immune Response
    • Machine Learning
    • Advocacy
  • Evidence
    • Publications
    • Abstracts
  • Pipeline
  • News
    • News
    • Press Releases
    • ML Blogs
    • Podcasts
    • Media Contact
  • Careers
  • About
    • Leadership
    • Investors
    • Partner With Us
    • Awards
    • Certificates
  • Reach Out
Select Page

Newsroom

Inflammatix in the news

Recent News
Infection-detection system from Peninsula company scores $102M, aims to hit market this year

Infection-detection system from Peninsula company scores $102M, aims to hit market this year

Mar 16, 2021
A Bright Future Ahead for Novel Markers of Infection

A Bright Future Ahead for Novel Markers of Infection

Dec 15, 2020
Inflammatix Awarded $7.4M in Additional BARDA Funding for POC System, Acute Infection Test

Inflammatix Awarded $7.4M in Additional BARDA Funding for POC System, Acute Infection Test

Oct 29, 2020
Older NewsRecent News
Inflammatix Nabs $6M from BARDA to Develop POC Acute Infection Diagnostic

Inflammatix Nabs $6M from BARDA to Develop POC Acute Infection Diagnostic

Nov 15, 2019
Inflammatix scores BARDA contract for infection tests

Inflammatix scores BARDA contract for infection tests

Nov 14, 2019
How $6 million could help a small Peninsula company spot deadly infections

How $6 million could help a small Peninsula company spot deadly infections

Nov 14, 2019
Inflammatix Inks BARDA Contract for up to $72M

Inflammatix Inks BARDA Contract for up to $72M

Nov 14, 2019
AACC panel votes Inflammatix technology most disruptive

AACC panel votes Inflammatix technology most disruptive

Sep 20, 2019
Inflammatix Preps Immune-Response Sepsis Dx for FDA Clinical Trial, Lays Out Future Test Plans

Inflammatix Preps Immune-Response Sepsis Dx for FDA Clinical Trial, Lays Out Future Test Plans

Aug 16, 2019
Older NewsRecent News

Press releases

Recent Press Releases

Machine learning blogs

Podcasts



Diagnosing Infection with Ljubomir Buturovic from Inflammatix

December 2023



Advances in Sepsis Diagnostics: the HostDx Sepsis Platform

May 2018

Media Contact

[email protected]

© Copyright 2025, Inflammatix, Inc. All Rights Reserved | Terms & Conditions | Privacy & Cookies Statement
Inflammatix, TriVerity, Myrna, RespVerity, and BacVerity are trademarks of Inflammatix, Inc.

  • Follow
  • Follow